Peter Kirkpatrick

Feb 6, 2025 | nature.com | Peter Kirkpatrick

Fifteen years ago, obesity drug development was out of favor, weighed down by limited efficacy and problems with side effects. But as recent clinical trials have shown strong weight-loss effects of glucagon-like peptide 1 (GLP-1) receptor agonists that were originally developed for type 2 diabetes, the field has ignited.

Oct 22, 2024 | nature.com | Peter Kirkpatrick

Last year was an outstanding period for deals focused on antibody–drug conjugates (ADCs), with Pfizer’s $43 billion acquisition of Seagen and AbbVie’s $10.1 billion buyout of ImmunoGen being among the highlights1. The popularity of the ADC platform has persisted in 2024, leading to several acquisitions and licensing deals with potential values in the billion-dollar range (as detailed in the deal snapshots).

May 14, 2024 | nature.com | Peter Kirkpatrick

Correction to: Nature Reviews Drug Discovery https://doi.org/10.1038/nrd3276, published online 1 October 2010In the version of the article initially published, there was an error in the chemical structure of roflumilast in Fig. 1. A revised Fig. 1 with the correct structure is shown below. This notice serves to correct the figure. About this articleFabbri, L.M., Beghé, B., Yasothan, U. et al. Publisher Correction: Roflumilast. Nat Rev Drug Discov (2024).